BioCryst Pharmaceuticals, Inc.
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930ā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.55
Price-1.14%
-$0.11
1Y
Price
Market Cap
$2.427b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-447.5%
EBITDA Margin-461.5%
Net Profit Margin-40.0%
Free Cash Flow Margin-447.5%
EBITDA Margin-461.5%
Net Profit Margin-40.0%
Free Cash Flow MarginRevenue
$885.716m
+1.2%
1y CAGR+43.8%
3y CAGR+38.4%
5y CAGREarnings
-$457.983m
-273.6%
1y CAGR+61.4%
3y CAGR+48.1%
5y CAGREPS
-$1.78
-247.1%
1y CAGR+66.0%
3y CAGR+52.3%
5y CAGRBook Value
-$553.843m
$465.052m
Assets$1.019b
Liabilities$858.083m
DebtDebt to Assets
184.5%
-2.3x
Debt to EBITDAFree Cash Flow
$294.098m
-10.2%
1y CAGR+250.4%
3y CAGR+197.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company